Second phase II trial of PCa immunotherapy begins
Dendreon Corp. has initiated its second of two new phase II trials of sipuleucel-T (Provenge), the company’s investigational active cellular immunotherapy for the treatment of advanced prostate cancer.
Dendreon Corp. has initiated its second of two new phase II trials of sipuleucel-T (Provenge), the company’s investigational active cellular immunotherapy for the treatment of advanced prostate cancer.
The multicenter ProACT (PROstate Active Cellular Therapy) trial has begun enrolling 120 patients with metastatic, androgen-independent prostate cancer to explore the effect of antigen concentration on CD54 upregulation as well as the immune response. Overall survival data will also be collected.
All patients will receive active treatment, but will be randomized into one of three cohorts that will receive different concentrations of the immunizing antigen. Patients will receive three infusions of the agent, each 2 weeks apart. Positive results from this study will serve as the basis for amendment of the company’s Biologics License Application for the investigational therapy.
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
UK study of AI-based software for prostate cancer detection expands
July 22nd 2024"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.
